Hemorrhagic cystitis (HC) is a common complication following hemopoietic stem cell transplantation (HSCT), its incidence ranging from 7 to 52% of all patients. Late occurring HC frequently results from viral infections. We describe a patient who developed severe polyomavirus-associated HC, which responded dramatically to a single dose of intra-muscular vidarabine. Previous studies show an improvement in HC with vidarabine therapy, but to date only the intravenous route of administration has been described and responses described take from several days to weeks. This report confirms the safety and efficacy of vidarabine administered intramuscularly when used in patients with an adequate platelet count, thereby making its use feasible when intravenous vidarabine is not available. Bone Marrow Transplantation (2000) 26, 1229-1230. Keywords: hemorrhagic cystitis; vidarabine; intra-muscular; transplantation Hemorrhagic cystitis (HC) is a common complication following hemopoietic stem cell transplantation (HSCT), its incidence ranging from 7 to 52% of all patients.
Hemorrhagic cystitis (HC) is a common complication following hemopoietic stem cell transplantation (HSCT), its incidence ranging from 7 to 52% of all patients. 1, 2 Early onset HC is associated with high-dose cyclophosphamide conditioning regimens and is prevented by the widespread use of the acrolein chelator mesna, hyperhydration or continuous bladder irrigation, while late occurring HC frequently results from viral infections (eg BK virus, adenovirus type 11). [3] [4] [5] BKV is a ubiquitous virus which infects more than 60% of the population worldwide at an early age. 6 Antibodies to BKV are demonstrated in the serum of 80 to 100% of adult patients before transplant. Since post-transplantation viruria only occurs in patients who were seropositive pre- transplantation, reactivation, probably associated with immune deficiency, is postulated to be the likely cause. 7 The purine analogue vidarabine (adenine arabinoside) has been shown to have in vitro antiviral activity against human polyomavirus by selectively inhibiting viral DNA polymerase. Successful treatment of polyomavirus-associated HC occurring after HSCT with disappearance or reduction in viruria has already been reported using intravenous vidarabine. 8 We describe a patient who developed severe polyomavirus-associated HC and who responded dramatically to a single dose of intra-muscular vidarabine, thereby demonstrating the efficacy and safety of this drug when employed intramuscularly.
Case report
A 13-year-old boy was diagnosed with severe aplastic anemia and underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical brother. After conditioning with cyclophosphamide (50 mg/kg for 3 days with mesna 50 mg/kg 0, 4 and 8 h after cyclophosphamide) and anti-thymocyte globulin (30 mg/kg for 3 days), 8.3 × 10 6
CD34
+ cells/kg were infused. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A at 1.5 mg/kg/12 h from day −4 onwards and methotrexate without folinic rescue on days +1, 3, 6 and 11.
More than 500 granulocytes/mm 3 and 20 × 10 9 platelets/l were achieved on days +14 and +12, respectively. Complete chimerism was demonstrated by molecular biology techniques on day +34.
On day +1 he developed moderate HC, which was managed with hyperhydration and bladder catheterization. Midstream urine cultures were negative. The catheter was removed on day +16 and he was discharged on day +21 with mild macroscopic hematuria but no other urinary symptoms. He was readmitted on day +34 with gross hematuria, presence of urinary blood clots and symptomatic anemia (Hb 8.5 g/dl). There were no coagulation abnormalities and platelet numbers remained within normal range throughout (ranging between 268 and 306 × 10 9 /l). Although hyperhydration was started, HC persisted causing anemia which required transfusion support: 10 units of irradiated packed red blood cells were necessary between days +36 and +47. Red cell transfusion requirements did not diminish prior to the antiviral therapy. The last two units were administered 24 h before beginning the vidarabine treatment.
Apart from the antiviral treatment for HC, no other changes in clinical management were introduced between days 45 and 49.
Virology studies of midstream urine samples collected on days +13, +35 and +40 showed amplification of BKV genomic DNA by PCR with specific primers. PCR for other polyomavirus was negative. Presence of adenovirus and CMV in urine was monitored by transmission electron microscopy and shell vial, respectively, and remained consistently negative throughout the follow-up period.
On day +47 vidarabine (10 mg/kg/day × 5 days) was started, but by the intramuscular rather than intravenous route. Urine sediment analysis on day +49 revealed no blood in the urine, hemoglobin levels remained stable thereafter and no further transfusions were needed. Urinary PCR BKV investigations on days +51 and +62 were negative.
Discussion
Hemorrhagic cystitis in recipients of allogeneic HSCT has been reported in association with the use of high-dose cyclophosphamide in the preparative regimen, viral infections with adenovirus and polyomavirus, and with GVHD. 9 Typically, cyclophosphamide-induced cystitis begins within 48 h of infusion while HC related to virus usually appears much later in the post-transplant period.
Some authors suggest that HC related to BK virus has a lengthy, albeit self-limiting course, and thus requires no specific treatment unless it becomes clearly symptomatic. 4 However, the safety and efficacy of agents such as vidarabine make treatment of HC a reasonable option before it turns into a more severe problem, especially since even uncomplicated HC is a stressful complication for patients.
In our patient, treatment with vidarabine was finally started due to severe bleeding requiring active red blood cell transfusion support. HC disappeared 24 h after vidarabine therapy was started and, in addition, urinary virus clearance was confirmed just 4 days after treatment.
It is also worth mentioning that HC in this patient started on day +1 although severe HC did not develop until day +34. Early HC has been associated with cyclophosphamide but, as shown in this case, even with early HC it is reasonable to exclude viral infection which may perpetuate HC, so that treatment may be started if clinically indicated.
Previous studies have shown an improvement in HC with vidarabine therapy, but to date only the intravenous route of administration has been described and responses have taken from several days to weeks to occur.
